Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Role of Intensive Glucose Control in Development of Renal End Points in Type 2 Diabetes Mellitus

Role of Intensive Glucose Control in Development of Renal End Points in Type 2 Diabetes Mellitus REVIEW ARTICLE Role of Intensive Glucose Control in Development of Renal End Points in Type 2 Diabetes Mellitus Systematic Review and Meta-analysis Steven G. Coca, DO, MS; Faramarz Ismail-Beigi, MD, PhD; Nowreen Haq, MD, MPH; Harlan M. Krumholz, MD, SM; Chirag R. Parikh, MD, PhD Background: Aggressive glycemic control has been hy- but not doubling of the serum creatinine level (1.06 pothesized to prevent renal disease in patients with type [0.92-1.22]), ESRD (0.69 [0.46-1.05]), or death from 2 diabetes mellitus. A systematic review was conducted renal disease (0.99 [0.55-1.79]). Meta-regression re- to summarize the benefits of intensive vs conventional vealed that larger differences in hemoglobin A be- 1c glucose control on kidney-related outcomes for adults tween intensive and conventional therapy at the study with type 2 diabetes. level were associated with greater benefit for both mi- croalbuminuria and macroalbuminuria. The pooled cu- Methods: Three databases were systematically searched mulative incidence of doubling of the serum creatinine ( January 1, 1950, to December 31, 2010) with no lan- level, ESRD, and death from renal disease was low guage restrictions to identify randomized trials that com- (4%, 1.5%, and 0.5%, respectively) compared pared surrogate renal end points (microalbuminuria and with the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Role of Intensive Glucose Control in Development of Renal End Points in Type 2 Diabetes Mellitus

Loading next page...
 
/lp/american-medical-association/role-of-intensive-glucose-control-in-development-of-renal-end-points-ZKVcWROAu9
Publisher
American Medical Association
Copyright
Copyright 2012 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/archinternmed.2011.2230
pmid
22636820
Publisher site
See Article on Publisher Site

Abstract

REVIEW ARTICLE Role of Intensive Glucose Control in Development of Renal End Points in Type 2 Diabetes Mellitus Systematic Review and Meta-analysis Steven G. Coca, DO, MS; Faramarz Ismail-Beigi, MD, PhD; Nowreen Haq, MD, MPH; Harlan M. Krumholz, MD, SM; Chirag R. Parikh, MD, PhD Background: Aggressive glycemic control has been hy- but not doubling of the serum creatinine level (1.06 pothesized to prevent renal disease in patients with type [0.92-1.22]), ESRD (0.69 [0.46-1.05]), or death from 2 diabetes mellitus. A systematic review was conducted renal disease (0.99 [0.55-1.79]). Meta-regression re- to summarize the benefits of intensive vs conventional vealed that larger differences in hemoglobin A be- 1c glucose control on kidney-related outcomes for adults tween intensive and conventional therapy at the study with type 2 diabetes. level were associated with greater benefit for both mi- croalbuminuria and macroalbuminuria. The pooled cu- Methods: Three databases were systematically searched mulative incidence of doubling of the serum creatinine ( January 1, 1950, to December 31, 2010) with no lan- level, ESRD, and death from renal disease was low guage restrictions to identify randomized trials that com- (4%, 1.5%, and 0.5%, respectively) compared pared surrogate renal end points (microalbuminuria and with the

Journal

JAMA Internal MedicineAmerican Medical Association

Published: May 28, 2012

References